HRP20110640T1 - Derivati cikličkih amida i njihova proizvodnja te njihova uporaba kao antitromboznih sredstava - Google Patents

Derivati cikličkih amida i njihova proizvodnja te njihova uporaba kao antitromboznih sredstava Download PDF

Info

Publication number
HRP20110640T1
HRP20110640T1 HR20110640T HRP20110640T HRP20110640T1 HR P20110640 T1 HRP20110640 T1 HR P20110640T1 HR 20110640 T HR20110640 T HR 20110640T HR P20110640 T HRP20110640 T HR P20110640T HR P20110640 T1 HRP20110640 T1 HR P20110640T1
Authority
HR
Croatia
Prior art keywords
optionally substituted
salt
chloronaphthalen
sulfonyl
hydroxypropanoyl
Prior art date
Application number
HR20110640T
Other languages
English (en)
Inventor
Kubo K.
Imaeda Y.
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of HRP20110640T1 publication Critical patent/HRP20110640T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Spoj, naznačen time, da je odabran između sljedećih: 4-(1-{(2S)-3-[(6-kloronaftalen-2-il)sulfonil]-2-hidroksipropanoil}piperidin-4-il)morfolin-3-on, ili njegova sol; 1-(4-{(2S)-3-[(6-kloronaftalen-2-il)sulfonil]-2-hidroksipropanoil}piperazin-1-il)piperidin-2-on, ili njegova sol; 1-(1-{(2S)-3-[(6-kloronaftalen-2-il)sulfonil]-2-hidroksipropanoil}piperidin-4-il)tetrahidropirimidin-2(1H)-on, ili njegova sol; 1-(4-{(2S)-3-[(6-kloronaftalen-2-il)sulfonil]-2-hidroksipropanoil}piperazin-1-il)tetrahidropirimidin-2(1H)-on, ili njegova sol; 1-(1-{3-[(6-kloronaftalen-2-il)sulfonil]propanoil}piperazin-4-il)tetrahidropirimidin-2(1H)-on, ili njegova sol; (2S)-3-[(6-kloronaftalen-2-il)sulfonil]-1-(2-imino-1,4'-bipiperidin-1'-il)-1-oksopropan-2-ol, ili njegova sol; 1'-{(2S)-3-[(6-kloronaftalen-2-il)sulfonil]-2-hidroksipropanoil}-1,4'-bipiperidin-2-on, ili njegova sol; i2-(1-{(2S)-3-[(6-kloronaftalen-2-il)sulfonil]-2-hidroksipropanoil}piperidin-4-il)izoindolin-1-on, ili njegova sol. Patent sadrži još 8 patentnih zahtjeva.

Claims (9)

1. Spoj, naznačen time, da je odabran između sljedećih: 4-(1-{(2S)-3-[(6-kloronaftalen-2-il)sulfonil]-2-hidroksipropanoil}piperidin-4-il)morfolin-3-on, ili njegova sol; 1-(4-{(2S)-3-[(6-kloronaftalen-2-il)sulfonil]-2-hidroksipropanoil}piperazin-1-il)piperidin-2-on, ili njegova sol; 1-(1-{(2S)-3-[(6-kloronaftalen-2-il)sulfonil]-2-hidroksipropanoil}piperidin-4-il)tetrahidropirimidin-2(1H)-on, ili njegova sol; 1-(4-{(2S)-3-[(6-kloronaftalen-2-il)sulfonil]-2-hidroksipropanoil}piperazin-1-il)tetrahidropirimidin-2(1H)-on, ili njegova sol; 1-(1-{3-[(6-kloronaftalen-2-il)sulfonil]propanoil}piperazin-4-il)tetrahidropirimidin-2(1H)-on, ili njegova sol; (2S)-3-[(6-kloronaftalen-2-il)sulfonil]-1-(2-imino-1,4'-bipiperidin-1'-il)-1-oksopropan-2-ol, ili njegova sol; 1'-{(2S)-3-[(6-kloronaftalen-2-il)sulfonil]-2-hidroksipropanoil}-1,4'-bipiperidin-2-on, ili njegova sol; i 2-(1-{(2S)-3-[(6-kloronaftalen-2-il)sulfonil]-2-hidroksipropanoil}piperidin-4-il)izoindolin-1-on, ili njegova sol.
2. Spoj prema zahtjevu 1, naznačen time, da je taj spoj 4-(1-{(2S)-3-[(6-kloronaftalen-2-il)sulfonil]-2-hidroksipropanoil}piperidin-4-il)morfolin-3-on, ili njegova sol.
3. Spoj prema zahtjevu 1, naznačen time, da je taj spoj 1-(4-{(2S)-3-[(6-kloronaftalen-2-il)sulfonil]-2-hidroksipropanoil}piperazin-1-il)piperidin-2-on, ili njegova sol.
4. Spoj prema zahtjevu 1, naznačen time, da je taj spoj 1-(1-{(2S)-3-[(6-kloronaftalen-2-il)sulfonil]-2-hidroksipropanoil}piperidin-4-il)tetrahidropirimidin-2(1H)-on, ili njegova sol.
5. Spoj prema zahtjevu 1, naznačen time, da je taj spoj 1-(4-{(2S)-3-[(6-kloronaftalen-2-il)sulfonil]-2-hidroksipropanoil}piperazin-1-il)tetrahidropirimidin-2(1H)-on, ili njegova sol.
6. Spoj prema zahtjevu 1, naznačen time, da je taj spoj 1-(1-{3-[(6-kloronaftalen-2-il)sulfonil]propanoil}piperazin-4-il)tetrahidropirimidin-2(1H)-on, ili njegova sol.
7. Spoj prema zahtjevu 1, naznačen time, da je taj spoj (2S)-3-[(6-kloronaftalen-2-il)sulfonil]-1-(2-imino-1,4'-bipiperidin-1'-il)-1-oksopropan-2-ol, ili njegova sol.
8. Spoj prema zahtjevu 1, naznačen time, da je taj spoj 1'-{(2S)-3-[(6-kloronaftalen-2-il)sulfonil]-2-hidroksipropanoil}-1,4'-bipiperidin-2-on, ili njegova sol.
9. Spoj prema zahtjevu 1, naznačen time, da je taj spoj 2-(1-{(2S)-3-[(6-kloronaftalen-2-il)sulfonil]-2-hidroksipropanoil}piperidin-4-il)izoindolin-1-on, ili njegova sol.
HR20110640T 2004-05-21 2011-09-07 Derivati cikličkih amida i njihova proizvodnja te njihova uporaba kao antitromboznih sredstava HRP20110640T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004152000 2004-05-21
PCT/JP2005/009711 WO2005113504A1 (en) 2004-05-21 2005-05-20 Cyclic amide derivatives, and their production and use as antithrombotic agents

Publications (1)

Publication Number Publication Date
HRP20110640T1 true HRP20110640T1 (hr) 2011-10-31

Family

ID=34968275

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110640T HRP20110640T1 (hr) 2004-05-21 2011-09-07 Derivati cikličkih amida i njihova proizvodnja te njihova uporaba kao antitromboznih sredstava

Country Status (26)

Country Link
US (4) US7745623B2 (hr)
EP (2) EP2208726B1 (hr)
JP (2) JP4129047B2 (hr)
KR (1) KR101248637B1 (hr)
CN (2) CN1989104B (hr)
AT (1) ATE513813T1 (hr)
AU (1) AU2005245298B2 (hr)
BR (1) BRPI0511186A (hr)
CA (1) CA2567506C (hr)
CY (1) CY1111850T1 (hr)
DK (1) DK1748985T3 (hr)
ES (1) ES2368155T3 (hr)
HK (1) HK1100666A1 (hr)
HR (1) HRP20110640T1 (hr)
IL (1) IL178896A (hr)
MX (1) MXPA06013243A (hr)
MY (1) MY154461A (hr)
NO (1) NO20065929L (hr)
NZ (1) NZ550985A (hr)
PL (1) PL1748985T3 (hr)
PT (1) PT1748985E (hr)
RS (1) RS51925B (hr)
RU (1) RU2361861C2 (hr)
SI (1) SI1748985T1 (hr)
TW (1) TWI396686B (hr)
WO (1) WO2005113504A1 (hr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1302462A4 (en) * 2000-07-17 2007-07-18 Takeda Pharmaceutical Sulphonic derivatives, process for their preparation and their use
WO2004048363A1 (ja) * 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
TWI396686B (zh) * 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
EP1960433A2 (en) * 2005-11-28 2008-08-27 Zymogenetics, Inc. Il-21 receptor antagonists
US20110045028A1 (en) * 2006-11-30 2011-02-24 Takeda Pharmaceutical Company Limited Sustained release preparation
UY32126A (es) 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
JPWO2010076884A1 (ja) 2008-12-29 2012-06-21 武田薬品工業株式会社 新規縮合環化合物およびその用途
AR075158A1 (es) 2009-01-27 2011-03-16 Takeda Pharmaceutical Derivados de pirrolopirimidinas, composiciones farmaceuticas y usos.
AU2010242308A1 (en) 2009-04-30 2011-12-01 Takeda Pharmaceutical Company Limited Solid preparation
US20120172351A1 (en) 2009-06-09 2012-07-05 Nobuyuki Negoro Novel fused cyclic compound and use thereof
CN102548556A (zh) 2009-07-28 2012-07-04 武田药品工业株式会社 片剂
US8221489B2 (en) * 2009-08-20 2012-07-17 Stentys Device and method for treating a body lumen
TW201206911A (en) 2010-04-27 2012-02-16 Takeda Pharmaceutical Bicyclic compound
TWI511967B (zh) 2010-06-16 2015-12-11 Takeda Pharmaceutical 醯胺化合物之結晶
WO2012011591A1 (ja) 2010-07-23 2012-01-26 武田薬品工業株式会社 縮合複素環化合物およびその用途
US20130184272A1 (en) 2010-09-17 2013-07-18 Takeda Pharmaceutical Company Limited Diabetes therapeutic agent
SG190925A1 (en) 2010-11-30 2013-07-31 Takeda Pharmaceutical Bicyclic compound
JP5945545B2 (ja) 2011-02-17 2016-07-05 武田薬品工業株式会社 光学活性なジヒドロベンゾフラン誘導体の製造法
CN103998432A (zh) 2011-10-24 2014-08-20 武田药品工业株式会社 双环化合物
JP6129850B2 (ja) 2012-01-12 2017-05-17 武田薬品工業株式会社 Ｍｃｈ受容体拮抗剤としてのベンゾイミダゾール誘導体
JP6121339B2 (ja) 2012-02-13 2017-04-26 武田薬品工業株式会社 芳香環化合物
JP6095580B2 (ja) 2012-02-13 2017-03-15 武田薬品工業株式会社 芳香環化合物
EP2814466B1 (en) 2012-02-15 2018-12-26 Takeda Pharmaceutical Company Limited Tablet comprising 1-(4-methoxybutyl)-n-(2-methylpropyl)-n-[(3s,5r)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-1h-benzimidazole-2-carboxamide or a salt thereof
CA2864990C (en) 2012-02-24 2021-03-02 Nobuyuki Takakura Benzofuran and benzothiophene compounds for the inhibition of ghrelin o-acyltranferase (goat)
CN104350040B (zh) 2012-03-29 2016-06-01 武田药品工业株式会社 芳环化合物
JPWO2013168759A1 (ja) 2012-05-10 2016-01-07 武田薬品工業株式会社 芳香環化合物
WO2013168760A1 (ja) 2012-05-10 2013-11-14 武田薬品工業株式会社 芳香環化合物
AR092843A1 (es) 2012-06-05 2015-05-06 Takeda Pharmaceuticals Co Preparacion solida
JP2015127299A (ja) 2012-07-19 2015-07-09 武田薬品工業株式会社 固形製剤
CA2882879A1 (en) 2012-08-24 2014-02-27 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN103936763B (zh) * 2013-01-18 2017-10-31 中国科学院上海药物研究所 噁唑烷酮类化合物及其制备方法和用途
EP2970331B1 (en) 2013-03-14 2017-05-17 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists
WO2014165816A1 (en) 2013-04-05 2014-10-09 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
JP2016523809A (ja) 2013-07-09 2016-08-12 武田薬品工業株式会社 複素環化合物
US9776962B2 (en) 2013-08-09 2017-10-03 Takeda Pharmaceutical Company Limited Aromatic compounds with GPR40 agonistic activity
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
JP2017529401A (ja) * 2014-09-26 2017-10-05 チャーンジョウ インシュヨン ファーマシューティカル カンパニー，リミティド Ｎｓ４ｂ阻害剤としてのベンゾフラン類似体
CN107108530B (zh) 2014-12-23 2020-12-15 克洛星有限公司 2-卤素-4,6-二烷氧基-1,3,5-三嗪的工业生产方法以及其在胺存在下的用途
AR111199A1 (es) 2017-03-31 2019-06-12 Takeda Pharmaceuticals Co Compuesto aromático agonista de gpr40
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
CA3058578A1 (en) 2017-03-31 2018-10-04 Takeda Pharmaceutical Company Limited Aromatic compound
US11207312B2 (en) 2017-07-17 2021-12-28 Merck Sharp & Dohme Corp. Metallo-beta-lactamase inhibitors and methods of use thereof
KR20210008834A (ko) 2018-03-23 2021-01-25 카모트 테라퓨틱스, 인크. G-단백질 결합 수용체의 조절제
EP3650440A4 (en) 2018-08-27 2020-11-25 Scohia Pharma, Inc. BENZOIC ESTER COMPOUND
JP2022503793A (ja) 2018-09-24 2022-01-12 武田薬品工業株式会社 Ｇｉｐ受容体アゴニストペプチド化合物及びその使用
EP3856339A1 (en) 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
AR121649A1 (es) 2020-03-25 2022-06-22 Takeda Pharmaceuticals Co Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos
KR20230005184A (ko) 2020-03-25 2023-01-09 다케다 야쿠힌 고교 가부시키가이샤 Gip 수용체 작용제 펩티드 화합물의 qd 투약 및 이의 용도
BR112023023559A2 (pt) 2021-05-13 2024-02-06 Carmot Therapeutics Inc Moduladores de receptores acoplados à proteína g
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024125602A1 (en) 2022-12-15 2024-06-20 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity
WO2024131869A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024138048A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024169952A1 (en) 2023-02-16 2024-08-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US270488A (en) * 1883-01-09 Drilling apparatus
US2201270A (en) * 1936-04-17 1940-05-21 Mcintyre John Taylor Apparatus for allaying dust from rock drills
US2946565A (en) * 1953-06-16 1960-07-26 Jersey Prod Res Co Combination drilling and testing process
US2849214A (en) * 1954-09-02 1958-08-26 Gulf Research Development Co Borehole drilling apparatus for preventing lost circulation
US3497020A (en) * 1968-05-20 1970-02-24 Archer W Kammerer Jr System for reducing hydrostatic pressure on formations
JPS5011391B1 (hr) * 1970-07-21 1975-04-30
SE355840B (hr) * 1971-09-08 1973-05-07 Atlas Copco Ab
FR2228301B1 (hr) * 1973-05-03 1977-10-14 Ibm
US4147786A (en) * 1976-02-02 1979-04-03 Ciba-Geigy Corporation 1-Indolylalkyl-3-or 4-trimethyleneurido-piperidines
FI782133A (fi) 1977-07-08 1979-01-09 Ciba Geigy Ag Piperidino-propanoler och foerfarande foer deras framstaellning
EP0000485A1 (de) 1977-07-08 1979-02-07 Ciba-Geigy Ag Piperidino-propanole, ihre Herstellung und pharmazeutische Präparate die diese enthalten
US4329348A (en) 1979-02-26 1982-05-11 Ciba-Geigy Corporation N-Oxacyclic-alkylpiperidines as psychostimulants
US4630691A (en) * 1983-05-19 1986-12-23 Hooper David W Annulus bypass peripheral nozzle jet pump pressure differential drilling tool and method for well drilling
US4534426A (en) * 1983-08-24 1985-08-13 Unique Oil Tools, Inc. Packer weighted and pressure differential method and apparatus for Big Hole drilling
US4567954A (en) * 1983-12-02 1986-02-04 Norton Christensen, Inc. Replaceable nozzles for insertion into a drilling bit formed by powder metallurgical techniques and a method for manufacturing the same
US4695575A (en) * 1984-11-13 1987-09-22 Janssen Pharmaceutica, N.V. 4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
US5902272A (en) * 1992-01-07 1999-05-11 Arthrocare Corporation Planar ablation probe and method for electrosurgical cutting and ablation
HU218419B (hu) 1992-03-06 2000-08-28 E.R. Squibb And Sons, Inc. Mikroszomális triglicerid transzfer protein (MTP) nagy molekulatömegű alegységének rekombináns úton történő előállítására és a protein és inhibitorainak kimutatására szolgáló eljárások
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5355967A (en) * 1992-10-30 1994-10-18 Union Oil Company Of California Underbalance jet pump drilling method
GB9321557D0 (en) 1992-11-03 1993-12-08 Zeneca Ltd Carboxamide derivatives
GB9312806D0 (en) 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
GB9317104D0 (en) 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
ZA951617B (en) * 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5456326A (en) * 1994-04-18 1995-10-10 Exxon Production Research Company Apparatus and method for installing open-ended tubular members axially into the earth
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
JP2002515008A (ja) 1994-10-27 2002-05-21 メルク エンド カンパニー インコーポレーテッド ムスカリン・アンタゴニスト
ATE233240T1 (de) 1994-12-02 2003-03-15 Yamanouchi Pharma Co Ltd Neues amidinonaphthylderivat oder dessen salz
GB9508786D0 (en) * 1995-04-29 1995-06-21 Zeneca Ltd Substituted heterocycles
DE69533991T2 (de) 1995-05-29 2006-04-13 Pfizer Inc. Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
US5612353A (en) 1995-06-07 1997-03-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
GB9602294D0 (en) 1996-02-05 1996-04-03 Zeneca Ltd Heterocyclic compounds
IL129877A (en) 1996-11-27 2004-08-31 Aventis Pharm Prod Inc A pharmaceutical preparation containing a component having an Xa antagonist activity and an antifouling agent
DE69835430T2 (de) 1997-05-30 2007-03-08 Takeda Pharmaceutical Co. Ltd. Sulfonamidderivate, ihre herstellung und verwendung
FR2764511B1 (fr) 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
GB9715895D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
US6348478B1 (en) 1997-11-20 2002-02-19 Teijin Limited Biphenylamidine derivatives
IL135408A0 (en) 1997-11-21 2001-05-20 Schering Corp Substituted oximes as neurokinin antagonists
WO1999033805A1 (fr) 1997-12-26 1999-07-08 Mochida Pharmaceutical Co., Ltd. Composes aromatiques presentant des groupements amino cycliques ou leur sels
CA2317017A1 (en) 1998-02-05 1999-08-12 Takeda Chemical Industries, Ltd. Sulfonamide derivatives, their production and use
EP1070714B1 (en) * 1998-04-10 2004-08-04 Japan Tobacco Inc. Amidine compounds
US6129152A (en) * 1998-04-29 2000-10-10 Alpine Oil Services Inc. Rotating bop and method
GB9809349D0 (en) 1998-05-02 1998-07-01 Zeneca Ltd Heterocyclic derivatives
US6423519B1 (en) * 1998-07-15 2002-07-23 Gpc Biotech Inc. Compositions and methods for inhibiting fungal growth
CA2340100A1 (en) 1998-08-11 2000-02-24 Daiichi Pharmaceutical Co., Ltd. Novel sulfonyl derivatives
JP2000080046A (ja) * 1998-09-03 2000-03-21 Dai Ichi Seiyaku Co Ltd 多臓器障害の予防・治療剤
EP1115396A4 (en) 1998-09-25 2002-05-22 Sunol Molecular Corp PHARMACEUTICALLY ACTIVE COMPOUNDS, AND METHODS OF USE THEREOF
CA2355886C (en) 1998-12-23 2006-10-31 Schering Corporation Substituted oximes and hydrazones as neurokinin antagonists
US6204265B1 (en) * 1998-12-23 2001-03-20 Schering Corporation Substituted oximes and hydrazones as neurokinin antagonists
US7217714B1 (en) 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
CA2383492A1 (en) 1999-06-22 2000-12-28 Takeda Chemical Industries, Ltd. Acylhydrazine derivatives, their production and use
DE60015541T2 (de) 1999-06-30 2005-12-08 Mochida Pharmaceutical Co. Ltd. Trizyklische verbindungen mit einer spiro-einheit
DE60041584D1 (de) 1999-07-28 2009-04-02 Aventis Pharma Inc Substituierte oxoazaheterozyclische verbindungen
AU7354900A (en) 1999-09-09 2001-04-10 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
EP1242366A1 (en) 1999-12-15 2002-09-25 Axys Pharmaceuticals, Inc. Salicylamides as serine protease and factor xa inhibitors
US6723091B2 (en) * 2000-02-22 2004-04-20 Gyrus Medical Limited Tissue resurfacing
US6629974B2 (en) * 2000-02-22 2003-10-07 Gyrus Medical Limited Tissue treatment method
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
JP2002201178A (ja) * 2000-07-17 2002-07-16 Takeda Chem Ind Ltd スルホン誘導体、その製造法及び用途
EP1302462A4 (en) * 2000-07-17 2007-07-18 Takeda Pharmaceutical Sulphonic derivatives, process for their preparation and their use
US6511973B2 (en) * 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
WO2002026720A2 (en) 2000-09-29 2002-04-04 Millennium Pharmaceuticals, Inc. PIPERAZINE BASED INHIBITORS OF FACTOR Xa
EP1331892B1 (en) * 2000-10-18 2006-07-05 Mattioli Engineering Limited Apparatus for plasma skin resurfacing
FR2819511A1 (fr) 2001-01-18 2002-07-19 Servier Lab Nouveaux composes azepane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JPWO2002068407A1 (ja) 2001-02-28 2004-06-24 山之内製薬株式会社 ベンゾイミダゾール化合物
ES2298386T3 (es) 2001-07-26 2008-05-16 Eli Lilly And Company 1-glicinil-4-(1-metilpiperidin-4-il)piperazinas y -piperidinas como antagonistas del factor xa.
US6877571B2 (en) * 2001-09-04 2005-04-12 Sunstone Corporation Down hole drilling assembly with independent jet pump
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
PL204263B1 (pl) 2001-09-21 2009-12-31 Bristol Myers Squibb Co Pochodna 1H-pirazolo[3,4-c]pirydyny i jej zastosowanie oraz kompozycja farmaceutyczna i jej zastosowanie
EP2243776A1 (en) * 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
DE10155075A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Cyclische Sulfonamide
DE60330847D1 (de) * 2002-03-28 2010-02-25 Mitsubishi Tanabe Pharma Corp Benzofuranderivat
TW200307667A (en) * 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
DE10229070A1 (de) 2002-06-28 2004-01-15 Merck Patent Gmbh Phenylderivate 5
US20040006490A1 (en) 2002-07-08 2004-01-08 Gingrich Mark A. Prescription data exchange system
EP1558606A4 (en) * 2002-10-02 2008-05-07 Bristol Myers Squibb Co DIAMINOALKYL CONTAINING LACTAM, BETA AMINO ACIDS, ALPHA AMINO ACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
WO2004035579A1 (ja) 2002-10-15 2004-04-29 Takeda Pharmaceutical Company Limited イミダゾピリジン誘導体、その製造法および用途
WO2004048363A1 (ja) * 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
MXPA05008878A (es) * 2003-02-21 2005-10-05 Pfizer Derivados de aminotiazol sustituidos con cicloalquilo que contiene n y composiciones farmaceuticas para inhibir la proliferacion celular, y metodos para su uso.
US6899188B2 (en) * 2003-03-26 2005-05-31 Sunstone Corporation Down hole drilling assembly with concentric casing actuated jet pump
WO2005087266A1 (en) 2004-03-05 2005-09-22 Vddi Pharmaceuticals Combination therapy for inhibition of platelet aggregation
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US7988933B2 (en) 2006-09-01 2011-08-02 Siemens Healthcare Diagnostics Inc. Identification system for a clinical sample container
KR100906250B1 (ko) 2006-09-04 2009-07-07 주식회사 엘지화학 바인더로서 고중합도 폴리비닐알콜과 폴리비닐피롤리돈의혼합물을 포함하는 전극 합제 및 이를 포함하는 리튬이차전지

Also Published As

Publication number Publication date
US20080255362A1 (en) 2008-10-16
JP4362535B2 (ja) 2009-11-11
JP2008500385A (ja) 2008-01-10
CA2567506A1 (en) 2005-12-01
EP1748985A1 (en) 2007-02-07
NZ550985A (en) 2011-02-25
ES2368155T3 (es) 2011-11-14
JP2008163030A (ja) 2008-07-17
SI1748985T1 (sl) 2011-08-31
MXPA06013243A (es) 2007-02-08
US20070244118A1 (en) 2007-10-18
MY154461A (en) 2015-06-30
BRPI0511186A (pt) 2007-12-04
CN1989104A (zh) 2007-06-27
RU2361861C2 (ru) 2009-07-20
EP2208726B1 (en) 2014-08-20
PL1748985T3 (pl) 2011-11-30
CN102093285B (zh) 2013-10-16
US7745623B2 (en) 2010-06-29
KR20070021205A (ko) 2007-02-22
US20080255352A1 (en) 2008-10-16
JP4129047B2 (ja) 2008-07-30
US8697865B2 (en) 2014-04-15
PT1748985E (pt) 2011-07-29
DK1748985T3 (da) 2011-08-29
IL178896A0 (en) 2007-03-08
IL178896A (en) 2012-07-31
KR101248637B1 (ko) 2013-03-28
ATE513813T1 (de) 2011-07-15
AU2005245298A1 (en) 2005-12-01
RS51925B (en) 2012-02-29
TW200600508A (en) 2006-01-01
TWI396686B (zh) 2013-05-21
US20100160629A1 (en) 2010-06-24
RU2006145449A (ru) 2008-06-27
CN1989104B (zh) 2011-07-13
EP2208726A1 (en) 2010-07-21
HK1100666A1 (en) 2007-09-28
AU2005245298B2 (en) 2011-04-07
CN102093285A (zh) 2011-06-15
CA2567506C (en) 2013-06-18
NO20065929L (no) 2007-02-19
CY1111850T1 (el) 2015-10-07
WO2005113504A1 (en) 2005-12-01
EP1748985B1 (en) 2011-06-22

Similar Documents

Publication Publication Date Title
HRP20110640T1 (hr) Derivati cikličkih amida i njihova proizvodnja te njihova uporaba kao antitromboznih sredstava
PE20090123A1 (es) Un derivado heterociclico conteniendo nitrogeno y un farmaco conteniendo el mismo como el ingrediente activo
PE20080209A1 (es) Derivados de glicina como inhibidores de prolil hidroxilasa
AR045587A1 (es) Derivados de acil piperazinas sustituidas, proceso de obtencion, uso y composiciones farmaceuticas que las contienen
PE20120635A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20040687A1 (es) Quinolinas sustituidas como antagonistas del receptor ccr5
AR057989A1 (es) Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas
NZ594597A (en) Substituted piperidines as ccr3 antagonists
PE20040780A1 (es) Compuestos heterociclicos como antagonista de cgrp y procedimiento para su preparacion
JP2008500385A5 (hr)
PE20110807A1 (es) Inhibidores de cinasa akt y p70 s6
NZ507119A (en) 1-[(4-Piperidinyl)methyl]-4-piperidine derivatives useful for treating gastrointestinal disorders
PE20060569A1 (es) Compuestos de indol carbonilamino como inhibidores de la polimerasa ne5b del vhc
PE20061130A1 (es) Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
PE20091090A1 (es) Derivados de piperidina como agonistas de receptores muscarinicos
PE20070839A1 (es) Derivados de indolobenzazepina como inhibidores de ns5b de vhc
PE20120229A1 (es) Compuestos heterociclicos como inhibidores de proteasa aspartica
NI200800036A (es) Inhibidores macrociclicos del virus de la hepatitis c
AR049696A1 (es) Derivados de indol
PE20090621A1 (es) Pirrolidina-aril-eteres como antagonistas de receptores de nk3
PE20091433A1 (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procedimientos para su preparacion 177
NZ594765A (en) Anthelmintic agents and their use
CA2569861A1 (en) Pyrrolidine derivatives as ccr5 antagonists
PE20090482A1 (es) Derivados heterociclicos como antagonistas del receptor ccr2
PE20081375A1 (es) Derivados octahidro-pirrolo[3,4-c]pirrol como antagonistas del receptor ccr5